Citadel Advisors
NRXP icon

Citadel Advisors’s NRX Pharmaceuticals NRXP Stock Holding History

Citadel Advisors’s Portfolio NRXP Stock Details NRXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-92,361
Closed -$264K – 13678
2025
Q2 		$301K Buy
+92,361
New +$232K ﹤0.01% 9818
2023
Q3 		– Sell
-25
Closed -$83 – 14820
2023
Q2 		$119 Hold
25
– – ﹤0.01% 14217
2023
Q1 		$163 Sell
25
-1,231
-98% -$12.5K ﹤0.01% 14559
2022
Q4 		$13.9K Buy
+1,256
New +$12.7K ﹤0.01% 13414
2022
Q3 		– Sell
-9,167
Closed -$61.8K – 13277
2022
Q2 		$55K Buy
+9,167
New +$120K ﹤0.01% 11870
2021
Q4 		– Sell
-13,509
Closed -$975K – 14443
2021
Q3 		$1.25M Buy
+13,509
New +$1.76M ﹤0.01% 7554

Other funds holding NRXP

BGI
B Group Inc Dallas, Texas $135M AUM 80% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BFG
Bleakley Financial Group Fairfield, New Jersey $6.39B AUM 26.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Citadel Advisors's NRXP Position: Q3 2025 in Review

Citadel Advisors sold out of NRX Pharmaceuticals (NRXP) in Q3 2025, closing a stake of 92,361 shares — an estimated $264K sold.

Citadel Advisors first reported a position in NRXP in Q3 2021 and held it in 6 quarters. The position peaked at $1.25M in Q3 2021. 24 funds tracked by Wall St. Rank hold NRXP as of Q3 2025.

  • Citadel Advisors reported no remaining NRX Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Citadel Advisors sold 92,361 NRX Pharmaceuticals shares in Q3 2025, an estimated $264K.
  • Citadel Advisors first reported a position in NRX Pharmaceuticals in Q3 2021 and held it in 6 quarters.
  • Citadel Advisors's NRX Pharmaceuticals position peaked at $1.25M in Q3 2021.
  • 24 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q3 2025.

Based on Citadel Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.